Unanswered Questions Following Reports of Secondary Malignancies After Car-T Cell Therapy

Authors

Bruce L Levine
Marcelo C Pasquini
John E Connolly
David L Porter
Michael P Gustafson
Jaap J Boelens
Edwin M Horwitz
Stephan A Grupp
Marcela V Maus
Frederick L Locke
Fabio Ciceri
Annalisa Ruggeri
John Snowden
Helen E Heslop
Crystal L Mackall
Carl H June
Anna M Sureda
Miguel-Angel Perales

Language

English

Publication Date

2-1-2024

Journal

Nature Medicine

DOI

10.1038/s41591-023-02767-w

PMID

38195751

PMCID

PMC11688691

PubMedCentral® Posted Date

1-1-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

Keywords

Humans, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Lymphoma, B-Cell, Cell- and Tissue-Based Therapy, Hematologic Neoplasms

Published Open-Access

yes

Recommended Citation

Levine, Bruce L; Pasquini, Marcelo C; Connolly, John E; et al., "Unanswered Questions Following Reports of Secondary Malignancies After Car-T Cell Therapy" (2024). Faculty and Staff Publications. 1562.
https://digitalcommons.library.tmc.edu/baylor_docs/1562